Innovating Works

PIUR tUS

Financiado
Tomographic 3D Ultrasound for Safe and More Cost Effective Vascular Diagnostics...
Tomographic 3D Ultrasound for Safe and More Cost Effective Vascular Diagnostics and Treatment Planning Annually, cardiovascular disease (CVD) causes over 4m deaths in Europe and 17.3m deaths globally, and is expected to grow to over 23.6m by 2030. It accounts for 40% of deaths in the EU and costs the EU economy almost €196bn each y... Annually, cardiovascular disease (CVD) causes over 4m deaths in Europe and 17.3m deaths globally, and is expected to grow to over 23.6m by 2030. It accounts for 40% of deaths in the EU and costs the EU economy almost €196bn each year. 2D ultrasound scans are currently the primary choice for vascular diagnostics. Due to low sensitivity, a limited field of action and the lack of volume information, patients are often referred for CTa, MRa and catheter angiography for the detailed imaging required for diagnosis and treatment planning. Referrals delay treatment, exposes the patient to risks associated with radiation and contrast mediums and increases costs. This presents a need to improve the speed and safety of the diagnosis of vascular conditions for rapid treatment, as well as to improve workflow efficiency and reduce costs. The project consortium will further develop the piur tUS system, a 3D freehand tomographic US system capable of rapid, safe and accurate reconstructive 3D quantifiable vascular imaging. It will provide a low cost and reproducible imaging solution that will reduce the need for referrals and be an effective preventative screening tool for CVD. We aim to complete and publish the results from 4 CVD clinical studies to generate the clinical evidence required for CE marking and clinical validation for market uptake. The 4 clinical applications studied will provide a solution for conditions most frequently referred for detailed 3D imaging to maximise the cost-benefit to clinics of purchasing the piur tUS system. The project consortium combines piur imaging’s expertise in medical device development and commercialisation with 3D imaging specialist ImFusion GmbH and medical device product development and manufacturing experts ACMIT. The clinical input for the product development and the clinical studies will be provided by our consortium partners, Independent Vascular Services Ltd and the Institute for Cardiovascular Science: University of Manchester ver más
31/10/2019
IVS
3M€
Duración del proyecto: 28 meses Fecha Inicio: 2017-06-07
Fecha Fin: 2019-10-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2019-10-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
FTIPilot-01-2016: Fast Track to Innovation Pilot
Cerrada hace 8 años
Presupuesto El presupuesto total del proyecto asciende a 3M€
Líder del proyecto
INDEPENDENT VASCULAR SERVICES LIMITED No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5